Trial Profile
Safety and Tolerability of Single Rising Doses of 1 mg, 3 mg, 10 mg and 20 mg of BIBF 1120 as Intravenous Infusion (Single-blind, Placebo controlled at Each Dose Group) and Absolute Bioavailability of 100 mg BIBF 1120 as Soft Gelatine Capsule (Intra-individual Comparison)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Nintedanib (Primary)
- Indications Colorectal cancer; Idiopathic pulmonary fibrosis; Liver cancer; Mesothelioma; Non-small cell lung cancer; Peritoneal cancer; Solid tumours; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 15 Jul 2014 New trial record